home > ict > autumn 2017 > time to listen
International Clinical Trials

Time to Listen

The new era of 2.0 technologies has welcomed the science
of pharmacovigilance (PV) with increasing interest from
regulatory agencies, pharmaceutical companies, healthcare
providers and patients, who may be seen as the leaders of
this evolution – as consumers of health-related products, the
collective voice of patients is having a significant impact. This
is contemporary to an observed shift from evidence-based
medicine towards real world evidence and observational
studies. In these, a study’s design is more fitted to patient life
than in controlled clinical trials, where eligible participants
must adapt to study settings.

Social media platforms, like Facebook, Twitter, and
Instagram, along with health-related websites and forums,
such as PatientsLikeMe or pharma-sponsored websites,
offer large forums of expression where any health-related
idea or concern may be shared, including adverse events
attributed to medications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

As Senior Safety Scientist at UBC, Caroline Legendre is responsible for supporting operational PV functions, including client interface, deliverables related to product safety and safety signal detection and assessment. She has 10 years of experience in the global pharmaceutical industry, with expertise in vaccines, pre- and post-marketing PV and pharmacoepidemiology.

Alexis Pinçon is Safety Physician at UBC and responsible for providing medical support to operational PV functions. He completed his medical training at the University of Lyon, France, and received his Master of Public Health from Université Besançon (Franche-Comté) in 2007. He has 10 years’ experience in PV within the pharma industry, primarily focused on vaccines in both clinical development and post-marketing.
Caroline Legendre
Alexis Pinçon
Print this page
Send to a friend
Privacy statement
News and Press Releases

Webinar: The Faster Path to Market

On March 22, 2018, SHL Group will hold a live webinar to discuss how pharmaceutical companies can leverage a preconfigured device technology to bring their innovative drug formulations to market more efficiently.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach


Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement